249 related articles for article (PubMed ID: 21989146)
1. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.
Basu PP; Rayapudi K; Pacana T; Shah NJ; Krishnaswamy N; Flynn M
Am J Gastroenterol; 2011 Nov; 106(11):1970-5. PubMed ID: 21989146
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
Assem M; El Azab G; Rasheed MA; Abdelfatah M; Shastery M
Eur J Intern Med; 2010 Aug; 21(4):310-4. PubMed ID: 20603042
[TBL] [Abstract][Full Text] [Related]
3. Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer.
Ermis F; Akyuz F; Uyanikoglu A; Kurt R; Pinarbasi B; Nazik H; Kaymakoglu S; Mungan Z
South Med J; 2011 Aug; 104(8):579-83. PubMed ID: 21886067
[TBL] [Abstract][Full Text] [Related]
4. Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country.
Ahuja V; Dhar A; Bal C; Sharma MP
Aliment Pharmacol Ther; 1998 Jun; 12(6):551-5. PubMed ID: 9678815
[TBL] [Abstract][Full Text] [Related]
5. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
[TBL] [Abstract][Full Text] [Related]
6. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population.
Miwa H; Nagahara A; Sato K; Ohkura R; Murai T; Shimizu H; Watanabe S; Sato N
J Gastroenterol Hepatol; 1999 Apr; 14(4):317-21. PubMed ID: 10207779
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin.
Louw JA; Van Rensburg CJ; Moola S; Kotze D; Marks IN
Aliment Pharmacol Ther; 1998 Sep; 12(9):881-5. PubMed ID: 9768531
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
Miwa H; Yamada T; Sato K; Ohta K; Ohkura R; Murai T; Nagahara A; Takei Y; Ogihara T; Sato N
Dig Dis Sci; 2000 Jan; 45(1):77-82. PubMed ID: 10695617
[TBL] [Abstract][Full Text] [Related]
10. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Kawabata H; Habu Y; Tomioka H; Kutsumi H; Kobayashi M; Oyasu K; Hayakumo T; Mizuno S; Kiyota K; Nakajima M; Kimoto K; Inokuchi H; Kawai K
Aliment Pharmacol Ther; 2003 Jan; 17(2):259-64. PubMed ID: 12534411
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Treiber G; Wittig J; Ammon S; Walker S; van Doorn LJ; Klotz U
Arch Intern Med; 2002 Jan; 162(2):153-60. PubMed ID: 11802748
[TBL] [Abstract][Full Text] [Related]
12. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori.
Fennerty MB; Kovacs TO; Krause R; Haber M; Weissfeld A; Siepman N; Rose P
Arch Intern Med; 1998 Aug 10-24; 158(15):1651-6. PubMed ID: 9701099
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS
Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938
[TBL] [Abstract][Full Text] [Related]
14. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
15. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.
Gisbert JP; Pérez-Aisa A; Bermejo F; Castro-Fernández M; Almela P; Barrio J; Cosme A; Modolell I; Bory F; Fernández-Bermejo M; Rodrigo L; Ortuño J; Sánchez-Pobre P; Khorrami S; Franco A; Tomas A; Guerra I; Lamas E; Ponce J; Calvet X;
J Clin Gastroenterol; 2013 Feb; 47(2):130-5. PubMed ID: 22647827
[TBL] [Abstract][Full Text] [Related]
16. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
[TBL] [Abstract][Full Text] [Related]
17. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
Gisbert JP; Bermejo F; Castro-Fernández M; Pérez-Aisa A; Fernández-Bermejo M; Tomas A; Barrio J; Bory F; Almela P; Sánchez-Pobre P; Cosme A; Ortiz V; Niño P; Khorrami S; Benito LM; Carneros JA; Lamas E; Modolell I; Franco A; Ortuño J; Rodrigo L; García-Durán F; O'Callaghan E; Ponce J; Valer MP; Calvet X;
Am J Gastroenterol; 2008 Jan; 103(1):71-6. PubMed ID: 17764498
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.
Molina-Infante J; Perez-Gallardo B; Fernandez-Bermejo M; Hernandez-Alonso M; Vinagre G; Dueñas C; Mateos-Rodriguez JM; Gonzalez-Garcia G; Abadia EG; Gisbert JP
Aliment Pharmacol Ther; 2010 May; 31(10):1077-84. PubMed ID: 20180787
[TBL] [Abstract][Full Text] [Related]
19. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Murakami K; Sato R; Okimoto T; Nasu M; Fujioka T; Kodama M; Kagawa J; Sato S; Abe H; Arita T
Aliment Pharmacol Ther; 2002 Nov; 16(11):1933-8. PubMed ID: 12390102
[TBL] [Abstract][Full Text] [Related]
20. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Asaka M; Kato M; Sugiyama T; Satoh K; Kuwayama H; Fukuda Y; Fujioka T; Takemoto T; Kimura K; Shimoyama T; Shimizu K; Kobayashi S;
J Gastroenterol; 2003; 38(4):339-47. PubMed ID: 12743773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
